Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

Claris Oh; Michael O’Callaghan

doi:10.1186/s12894-024-01507-7

Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

College of Medicine and Public Health

Research output: Contribution to journal › Comment/debate

40 Downloads (Pure)

Abstract

The ARASENS trial recruited 1306 men with metastatic hormone sensitive prostate cancer. It investigated the effect of androgen deprivation therapy (ADT) and systemic therapy docetaxel in combination with a third novel drug – daralutamide, compared with placebo on overall survival. Triple therapy with ADT, docetaxel and darolutamide resulted in improved overall survival rates as compared with ADT, docetaxel and placebo (HR 0.68; 95% CI, 0.57–0.80; p < 0.001). The side effect profile for both treatments was similar. This randomised, double blinded, placebo controlled study, was assessed to have a low risk of bias using the Cochrane Risk of Bias 2 tool.

Original language	English
Article number	135
Number of pages	3
Journal	BMC Urology
Volume	24
Issue number	1
DOIs	https://doi.org/10.1186/s12894-024-01507-7
Publication status	Published - 1 Jul 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Daralutamide
Metastatic
Prostate cancer
Survival

Access to Document

10.1186/s12894-024-01507-7Licence: CC BY

Final published versionFinal published version, 775 KBLicence: CC BY

Cite this

@article{a5ce3321d0104ee49c475cd53a914694,

title = "Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer",

abstract = "The ARASENS trial recruited 1306 men with metastatic hormone sensitive prostate cancer. It investigated the effect of androgen deprivation therapy (ADT) and systemic therapy docetaxel in combination with a third novel drug – daralutamide, compared with placebo on overall survival. Triple therapy with ADT, docetaxel and darolutamide resulted in improved overall survival rates as compared with ADT, docetaxel and placebo (HR 0.68; 95\% CI, 0.57–0.80; p < 0.001). The side effect profile for both treatments was similar. This randomised, double blinded, placebo controlled study, was assessed to have a low risk of bias using the Cochrane Risk of Bias 2 tool.",

keywords = "Daralutamide, Metastatic, Prostate cancer, Survival",

author = "Claris Oh and Michael O{\textquoteright}Callaghan",

year = "2024",

month = jul,

day = "1",

doi = "10.1186/s12894-024-01507-7",

language = "English",

volume = "24",

journal = "BMC Urology",

issn = "1471-2490",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Seminal Papers in Urology

T2 - Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

AU - Oh, Claris

AU - O’Callaghan, Michael

PY - 2024/7/1

Y1 - 2024/7/1

N2 - The ARASENS trial recruited 1306 men with metastatic hormone sensitive prostate cancer. It investigated the effect of androgen deprivation therapy (ADT) and systemic therapy docetaxel in combination with a third novel drug – daralutamide, compared with placebo on overall survival. Triple therapy with ADT, docetaxel and darolutamide resulted in improved overall survival rates as compared with ADT, docetaxel and placebo (HR 0.68; 95% CI, 0.57–0.80; p < 0.001). The side effect profile for both treatments was similar. This randomised, double blinded, placebo controlled study, was assessed to have a low risk of bias using the Cochrane Risk of Bias 2 tool.

AB - The ARASENS trial recruited 1306 men with metastatic hormone sensitive prostate cancer. It investigated the effect of androgen deprivation therapy (ADT) and systemic therapy docetaxel in combination with a third novel drug – daralutamide, compared with placebo on overall survival. Triple therapy with ADT, docetaxel and darolutamide resulted in improved overall survival rates as compared with ADT, docetaxel and placebo (HR 0.68; 95% CI, 0.57–0.80; p < 0.001). The side effect profile for both treatments was similar. This randomised, double blinded, placebo controlled study, was assessed to have a low risk of bias using the Cochrane Risk of Bias 2 tool.

KW - Daralutamide

KW - Metastatic

KW - Prostate cancer

KW - Survival

UR - https://www.scopus.com/pages/publications/85197308350

U2 - 10.1186/s12894-024-01507-7

DO - 10.1186/s12894-024-01507-7

M3 - Comment/debate

C2 - 38951868

AN - SCOPUS:85197308350

SN - 1471-2490

VL - 24

JO - BMC Urology

JF - BMC Urology

IS - 1

M1 - 135

ER -

Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this